APO-TELMISARTAN TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

TELMISARTAN

Disponibbli minn:

APOTEX INC

Kodiċi ATC:

C09CA07

INN (Isem Internazzjonali):

TELMISARTAN

Dożaġġ:

40MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

TELMISARTAN 40MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/100/500

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0138223001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2014-01-24

Karatteristiċi tal-prodott

_APO-TELMISARTAN Product Monograph_
Page 1 of 30
PRODUCT MONOGRAPH
Pr APO-TELMISARTAN
(TELMISARTAN TABLETS, USP)
40 MG AND 80 MG
ANGIOTENSIN II AT1 RECEPTOR BLOCKER
APOTEX INC.
DATE OF PREPARATION:
150 SIGNET DRIVE
JANUARY 24, 2014
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 149368
_APO-TELMISARTAN Product Monograph_
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
3
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
......................................................................................................
8
DRUG INTERACTIONS
......................................................................................................13
DOSAGE AND ADMINISTRATION
.....................................................................................15
OVERDOSAGE
...................................................................................................................15
ACTION AND CLINICAL PHARMACOLOGY
......................................................................16
STORAGE AND
STABILITY................................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................18
PART II: SCIENTIFIC INFORMATION
...................................................................................20
PHARMACEUTICAL INFORMATION
..................................................................................20
CLINICAL TRIALS
........................................................................